LITESPARK-012: pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab for advanced renal cell carcinoma

被引：3
作者：
Choueiri, Toni K. [1 ,2 ]
Powles, Thomas [3 ,4 ]
Voss, Martin H. [5 ]
Plimack, Elizabeth R. [6 ]
Gurney, Howard [7 ,8 ]
Song, Yue [9 ]
Perini, Rodolfo F. [9 ]
Rodriguez-Lopez, Karla [9 ]
Rini, Brian, I [10 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02215 USA
[2] Harvard Med Sch, Boston, MA 02115 USA
[3] Barts Hlth NHS Trust, London, England
[4] Queen Mary Univ London, Royal Free NHS Fdn Trust, Barts Canc Inst, London, England
[5] Mem Sloan Kettering Canc Ctr, New York, NY USA
[6] Fox Chase Canc Ctr, Philadelphia, PA USA
[7] Westmead Hosp, Sydney, NSW, Australia
[8] Macquarie Univ Hosp, Sydney, NSW, Australia
[9] Merck & Co Inc, Rahway, NJ USA
[10] Vanderbilt Ingram Canc Ctr, Nashville, TN USA
来源：
FUTURE ONCOLOGY | 2023年 / 19卷 / 40期
关键词：
clear cell renal cell carcinoma; CTLA-4; inhibitor; HIF-2 alpha inhibitor; immune checkpoint inhibitor; PD-1/L1; VEGFR-TKI; NIVOLUMAB; SUNITINIB; CANCER; CABOZANTINIB; COMBINATION; EFFICACY; BLOCKADE; SAFETY;
D O I：
10.2217/fon-2023-0283
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Combination treatment with immunotherapy agents and/or vascular endothelial growth factor tyrosine kinase inhibitors are a standard of care for patients with advanced clear cell renal cell carcinoma (ccRCC). Novel therapeutic combinations that include the hypoxia-inducible factor 2 alpha inhibitor belzutifan and the cytotoxic T-lymphocyte-associated protein 4 inhibitor quavonlimab are being investigated for their potential to further improve patient outcomes. This protocol describes the rationale and design of the randomized, phase III LITESPARK-012 study, which will evaluate the efficacy and safety of pembrolizumab plus lenvatinib with or without belzutifan or quavonlimab as first-line treatment for advanced ccRCC. Results from this study may support triplet combination therapies as a potential new standard of care for advanced ccRCC.
引用
收藏
页码：2631 / 2640
页数：10
相关论文
共 48 条
  • [1] [Anonymous], 2023, OPD NIV INJ INTR US
  • [2] [Anonymous], WEL BELZ TABL
  • [3] [Anonymous], LENVIMA LENV CAPS OR
  • [4] [Anonymous], 2022, MERK PRESS REL
  • [5] Beyond Traditional Outcomes: Improving Quality of Life in Patients with Renal Cell Carcinoma
    Cella, David
    [J]. ONCOLOGIST, 2011, 16 : 23 - 31
  • [6] Anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody quavonlimab in combination with pembrolizumab: Safety and efficacy from a phase I study in previously treated extensive-stage small cell lung cancer
    Cho, Byoung Chul
    Yoh, Kiyotaka
    Perets, Ruth
    Nagrial, Adnan
    Spigel, David R.
    Gutierrez, Martin
    Kim, Dong-Wan
    Kotasek, Dusan
    Rasco, Drew
    Niu, Jiaxin
    Satouchi, Miyako
    Ahn, Myung-Ju
    Lee, Dae Ho
    Maurice-Dror, Corinne
    Siddiqi, Shabana
    Ren, Yixin
    Altura, Rachel A.
    Bar, Jair
    [J]. LUNG CANCER, 2021, 159 : 162 - 170
  • [7] Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma
    Choueiri, T. K.
    Powles, T.
    Burotto, M.
    Escudier, B.
    Bourlon, M. T.
    Zurawski, B.
    Juarez, V. M. Oyervides
    Hsieh, J. J.
    Basso, U.
    Shah, A. Y.
    Suarez, C.
    Hamzaj, A.
    Goh, J. C.
    Barrios, C.
    Richardet, M.
    Porta, C.
    Kowalyszyn, R.
    Feregrino, J. P.
    Zolnierek, J.
    Pook, D.
    Kessler, E. R.
    Tomita, Y.
    Mizuno, R.
    Bedke, J.
    Zhang, J.
    Maurer, M. A.
    Simsek, B.
    Ejzykowicz, F.
    Schwab, G. M.
    Apolo, A. B.
    Motzer, R. J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2021, 384 (09) : 829 - 841
  • [8] From Basic Science to Clinical Translation in Kidney Cancer: A Report from the Second Kidney Cancer Research Summit
    Choueiri, Toni K.
    Albiges, Laurence
    Atkins, Michael B.
    Bakouny, Ziad
    Bratslavsky, Gennady
    Braun, David A.
    Haas, Naomi B.
    Haanen, John B. A. G.
    Hakimi, A. Ari
    Jewett, Michael A. S.
    Jonasch, Eric
    Kaelin, William G., Jr.
    Kapur, Payal
    Labaki, Chris
    Lewis, Bryan
    McDermott, David F.
    Pal, Sumanta K.
    Pels, Kevin
    Poteat, Susan
    Powles, Thomas
    Rathmell, W. Kimryn
    Rini, Brian, I
    Signoretti, Sabina
    Tannir, Nizar M.
    Uzzo, Robert G.
    Hammers, Hans J.
    [J]. CLINICAL CANCER RESEARCH, 2022, 28 (05) : 831 - 839
  • [9] Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma
    Choueiri, Toni K.
    Powles, Thomas
    Albiges, Laurence
    Burotto, Mauricio
    Szczylik, Cezary
    Zurawski, Bogdan
    Ruiz, Eduardo Yanez
    Maruzzo, Marco
    Zaizar, Alberto Suarez
    Fein, Luis E.
    Schutz, Fabio A.
    Heng, Daniel Y. C.
    Wang, Fong
    Mataveli, Fabio
    Chang, Yu-Lin
    van Kooten Losio, Maximiliano
    Suarez, Cristina
    Motzer, Robert J.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2023, 388 (19) : 1767 - 1778
  • [10] Belzutifan plus cabozantinib for patients with advanced clear cell renal cell carcinoma previously treated with immunotherapy: an open-label, single-arm, phase 2 study
    Choueiri, Toni K.
    McDermott, David F.
    Merchan, Jaime
    Bauer, Todd M.
    Figlin, Robert
    Heath, Elisabeth, I
    Michaelson, M. Dror
    Arrowsmith, Edward
    D'Souza, Anishka
    Zhao, Song
    Roy, Ananya
    Perini, Rodolfo
    Vickery, Donna
    Tykodi, Scott S.
    [J]. LANCET ONCOLOGY, 2023, 24 (05) : 553 - 562
12345